GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Microbio Co Ltd (ROCO:4128) » Definitions » Long-Term Capital Lease Obligation

Microbio Co (ROCO:4128) Long-Term Capital Lease Obligation : NT$427 Mil (As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Microbio Co Long-Term Capital Lease Obligation?

Microbio Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was NT$427 Mil.

Microbio Co's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (NT$448 Mil) to Dec. 2024 (NT$469 Mil) but then declined from Dec. 2024 (NT$469 Mil) to Mar. 2025 (NT$427 Mil).

Microbio Co's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (NT$371 Mil) to Dec. 2023 (NT$479 Mil) but then declined from Dec. 2023 (NT$479 Mil) to Dec. 2024 (NT$469 Mil).


Microbio Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Microbio Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbio Co Long-Term Capital Lease Obligation Chart

Microbio Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 382.17 400.07 370.81 478.80 468.55

Microbio Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 448.26 475.63 448.46 468.55 426.77

Microbio Co  (ROCO:4128) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Microbio Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Microbio Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbio Co Business Description

Traded in Other Exchanges
N/A
Address
Yuan Qu Street, No.3, 14th Floor, Sanchongli, Nangang District, Taipei, TWN, 115
Microbio Co Ltd is engaged in the research and development, manufacturing, and trading of biotech drugs and dietary supplements. Its drug portfolio includes MS-20, a mixture of soybean fermentation metabolites, which improves fatigue and loss of appetite in cancer patients undergoing chemotherapy. In addition, the company also offers Lee Herb series of herbal essence drinks, Tien Chun Bao oral solutions, Herbiron oral solutions for iron deficiency, and other pharmaceutical and organic products. The company generates revenue from biotech drug research and development, and the sale of dietary supplements. A majority of its revenue is generated from the sale of its dietary supplements.

Microbio Co Headlines

No Headlines